A phase II study of the HDAC inhibitor SB939 in patients with castration resistant prostate cancer: NCIC clinical trials group study IND195
Eigl, B. J., North, S., Winquist, E., Finch, D., Wood, L., Sridhar, S. S., Powers, J., Good, J., Sharma, M., Squire, J. A., Bazov, J., Jamaspishvili, T., Cox, M. E., Bradbury, P. A., Eisenhauer, E. A.Volume:
33
Language:
english
Journal:
Investigational New Drugs
DOI:
10.1007/s10637-015-0252-4
Date:
August, 2015
File:
PDF, 386 KB
english, 2015